Protocol Ledger

NCT06317662 · Phase II · RECRUITING

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leuk

Interventional Phase II clinical trial protocol NCT06317662 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-05 Enrollment: 153 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06317662
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)153 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06317662
Protocol FieldVerified Registry Value
NCT IdentifierNCT06317662
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment153 participants (ESTIMATED)
Registered Start Date2025-06-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06317662
Hospital Research SiteLocationSite Profile
Children's Hospital of AlabamaBirmingham, ALOpen Hospital Dossier ->
Providence Alaska Medical CenterAnchorage, AKOpen Hospital Dossier ->
Arkansas Children's HospitalLittle Rock, AROpen Hospital Dossier ->
Loma Linda University Medical CenterLoma Linda, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI